The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis of MSA disease.
Study Type
OBSERVATIONAL
Enrollment
90
Third Xiangya Hospital of Central South University
Hunan, Changsha, China
RECRUITINGStandard uptake value ratio(SUVR)
Time frame: From enrollment to the end of treatment at 4 weeks
UMSARS
Unified Multiple System Atrophy Rating Scale
Time frame: From enrollment to the end of treatment at 4 weeks
H-Y stage
Time frame: From enrollment to the end of treatment at 4 weeks
SCOPA-AUT
Parkinson's Disease Autonomic Symptoms Scale
Time frame: From enrollment to the end of treatment at 4 weeks
Wexner score
Wexner Continence Grading Scale
Time frame: From enrollment to the end of treatment at 4 weeks
Frontal Assessment Battery
Time frame: From enrollment to the end of treatment at 4 weeks
MoCA score
Montreal Cognitive Assessment
Time frame: From enrollment to the end of treatment at 4 weeks
TSPO Single nucleotide polymorphism genotyping
Time frame: From enrollment to the end of treatment at 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.